Bay­er sounds re­treat from a $670 mil­lion CAR-T pact in the wake of a pa­tient death

Two months af­ter Atara Bio­ther­a­peu­tics hit the hold but­ton on its lead CAR-T 2.0 ther­a­py fol­low­ing a pa­tient death, putting the com­pa­ny un­der the watch­ful …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER